The present invention is directed to a tamper evident closure assembly for a syringe or other medical device, and comprises a housing having an open end and a tip cap removably disposed therein. The tamper evident closure assembly of this invention also comprises an indicator member that is removably disposed in at least partially covering relation to the open end of the housing, and wherein a removal of the tip cap, when attached to the syringe or other medical device, results in a captured disposition of the indicator ring on the syringe or other medical device and attached tip cap, thereby providing a clear indication of tampering or use.
In the medical field, it is a relatively common procedure for authorized medical personnel to order a drug or medication which is to be administered by injection or other procedures, including by intravenous (IV) infusion. It is also relatively common procedure for a number of administering devices to be pre-loaded or filled by authorized personnel, whether within the hospital or at another facility and location, which may be generally referred to as a filling station. However, a filling station is typically located in a remote part of the hospital or other facility, relative to the patient care area where the injection is to be administered. Indeed, at large medical facilities, a filling station may resemble a factory on the hospital grounds from which drugs and other fluids are delivered to multiple nursing stations at different locations. Because of the remote location of many nurse's stations relative to a filling station, a fluid or drug loaded administering device is very often given to another person for delivery to a nurse's station for subsequent dosing of the patient by a duly qualified nurse or other medically trained person. As a result, a pre-loaded syringe may travel quite some distance and be handled by several people before it reaches a nurse's station, which raises some concern that the contents of the syringe may be tampered with or cause the sterility of the syringe and/or its contents to be comprises compromised.
Additionally, in the case where a drug has been prescribed that is very expensive or addictive, such as but not limited to morphine, and has been pre-loaded in the syringe or other administering device, there is an increased danger that the pre-loaded syringe or administering device will be tampered with at some point, by a person seeking unauthorized access to the drug. This possibility can present real danger in that such a person might gain access to the prescribed medicine and then, inappropriately and without concern, substitute some other, unauthorized substance in the syringe, which looks like the actual prescribed medicine and dosage. By way of an example only, if saline solution or water or another drug were substituted for a dose of morphine, the patient would not receive the prescribed drug which by itself, could be quite harmful, while the substituted content might potentially also cause extremely serious harm. Thus, there is a problem of knowing if a sealed, pre-loaded syringe or other administering device has, or has not, been exposed to contamination or might otherwise have been compromised by its being tampered with. This and related types of problems have been described in one or more previously issued U.S. patents granted to one of the inventors herein, such as U.S. Pat. No. 5,328,474. Therefore, to overcome the disadvantages and problems of utilizing a pre-filled syringe, a variety of “tamper evident structures” have been designed with a goal of preventing one from accessing the contents of a pre-filled syringe without authorization, or of at least indicating whether such access has been accomplished or attempted.
In addition, in the use of enteral feeding sets, and like medical devices or accessories, it is also important both to maintain sterility and provide an ability to indicate whether there has been any tampering with or unauthorized access. As commonly recognized in the medical and related professions, the term “enteral” relates to the administration of fluid, typically in the form of liquid, into the intestine, or gastrointestinal tract, such as via the mouth, esophagus or through an artificial opening. As referred to herein, various enteral connectors and/or connecting structures exist for medical devices and/or accessories intended for use in enteral applications and it would be helpful to develop a reliable closure for the same which prevents unauthorized access to such medical devices and/or connectors or indicates if tampering has occurred.
Also, with regard to administering fluids to a patient by intravenous (IV) infusion, a variety of IV assemblies are known and are useful in the treatment of a number of medical conditions, as a variety of fluids and/or medicines can be administered to a patient utilizing such assemblies over a prescribed period of time and in controlled amounts. In use, a conventional IV administration assembly typically includes a reservoir or container, in the form of a bottle or flexible material bag, disposed in an elevated, suspended location substantially adjacent to the patient being treated. In addition, the IV fluid flows from the supported and elevated IV bag to the patient by means of elongated, flexible tubing connected at a proximal end to the IV bag and at the other distal end, connected intravenously to the patient by way of a catheter or like structure. IV administering assemblies of this type will often include a luer connector, which may be structured to at least partially define a luer lock connector assembly, as is well known in the medical profession.
In periods of non-use, it is important to maintain such luer connectors in a closed and fluid-sealed condition in order to maintain sterility, and also, to maintain the integrity of the contents of a pre-loaded medical device (whether a syringe, bottle, flexible IV bag, etc.) prior to use. This is also important in order to restrict unauthorized access to the contents of the IV bag or other medical device and/or luer connector associated therewith.
Despite prior attempts to provide a closure to protect a medical device, connector for a medical device and/or the contents of pre-loaded syringes and other administering devices, certain problems still remain in this field of art. As such, there is a need for an improved closure that is capable of providing secure and reliable, fluid-restricting or fluid-sealing connection to the connector of a medical device and/or discharge structure associated with a pre-loaded syringe or other administering device, such as, but not limited to a luer connector or female structure associated with an enteral feeding set. If any such new closure assembly were developed, it should also have structural and operative features able to provide a clear and reliable indication that tampering or attempted tampering with and/or use of the patient administering device has occurred. Also, any such closure assembly should be capable of use, with little or no structural modifications, with a variety of different connectors, fixtures, administering devices, etc. Finally, any such improved closure assembly should also be structurally and operatively reliable, while still remaining cost effective to manufacture and assemble, in order to facilitate widespread use and acceptance throughout the medical profession.
The present invention is directed to a closure assembly having tamper evident capabilities and structured to be connected to a medical device such as, but not limited to, a syringe that has been pre-loaded with a drug or other medical prescribed substance, or another type of pre-loaded administering device. In addition, the closure assembly of the present invention is structured in one or more embodiments for attachment and/or connection to the medical device in “flow restricting relation” to a discharge port, such as a nozzle associated with the syringe, or other medical device.
The tamper evident closure assembly comprises a housing including an at least partially hollow interior and an open end disposed in direct communication with the hollow interior. In at least one embodiment, the opposite end of the housing is closed and includes structural components such as, but not limited to a “one-way” rotational drive assembly, as set forth in greater detail hereinafter.
The tamper evident closure assembly also comprises a tip cap that is removably disposed within the hollow interior of the housing in accessible relation to the open end of the housing. As indicated above, the tip cap may include different structural features and operational capabilities such as, but not limited to, a “flow restricting” portion or structure. When provided, the flow restricting portion of the tip cap is disposed and structured to engage and be connected to a discharge port, such as a nozzle associated with a syringe, or other discharge structure associated with a medical device with which it is used. As also described, the tamper evident closure assembly is adapted, in one or more embodiments, to be attached to and used in combination with a pre-loaded syringe or other pre-loaded medical device in a manner which protects and restricts access to the contents thereof, while preventing inadvertent flow of fluid contents from the syringe or medical device.
The tamper evident closure assembly of the present invention may additionally comprise a cover connected to the housing at or immediately adjacent to the open end thereof. In preferred embodiments, the cover is cooperatively structured relative to portions of the housing substantially contiguous to the open end thereof, to retain the tip cap within the hollow interior of the housing in an initial position prior to attachment to the discharge port of the syringe or other medical device. More specifically, the cover is cooperatively structured in preferred embodiments relative to the housing to provide for a “snap-fit” connection of the cover on the housing at and or immediately adjacent to the open end. Further, such a snap-fit connection serves to fixedly connect the cover to the housing at the open end, and results in an ability to assemble the closure assembly in an efficient, time-saving manner. That is, a “snap-fit” connection facilitates an easy and efficient attachment of the cover to the open end of the housing during assembly of the invention, and subsequent to the placement of the tip cap within the hollow interior thereof, because it eliminates the need for welding or other methods of fixed attachment during manufacturing of the closure assembly. As a result, such a fixed, snap-fit connection is also extremely advantageous in terms of saving time and reducing labor costs associated with manufacturing and assembling of the closure assembly.
The tamper evident closure assembly of the present invention also comprises an indicator member. In one or more preferred embodiments, the indicator member comprises an indicator ring having a substantially annular configuration. The indicator ring, as well as other configurations of the indicator member, is removably connected to the cover in at least partially overlying and/or covering relation to the open end of the housing. The indicator ring includes an access opening disposed and configured in aligned relation with the tip cap disposed within the housing. Further, the access opening is dimensioned and configured to facilitate access of the medical device, or at least the discharge port or structure thereof, to pass through the access opening into attachment with the tip cap. However, the size and interior dimension of the access opening is smaller than the tip cap, or at least certain portions of the tip cap, thereby preventing passage of the tip cap through the access opening of the indicator member, whether or not the tip cap is attached to the medical device. In more specific terms, the inner diameter or corresponding dimension of the access opening is less than the outer diameter of the base or largest portion of the tip cap. Therefore, when the indicator member or indicator ring is in position in at least partially covering relation to the open end of the housing, because of the smaller dimension of the access opening relative to the tip cap, the indicator member is disposed and structured to restrict removal or passage of the tip cap from the interior of the housing, through the open end thereof. This removal restricting capability of the indicator member exists both before the tip cap is attached to a syringe or other medical device, and after the tip cap (and closure assembly) has been attached to a syringe or other medical device.
As set forth in greater detail hereinafter, when the closure assembly is installed on syringe or medical device, a forced removal of the tip cap from the interior of the housing through the open end, will result in disconnection of the indicator member from the cover. Any such removal or disconnection of the indicator member, in whole or in part, from the housing serves to provide a clear visual indication of an at least attempted tampering with or use of the syringe or medical device. Similarly, if there is any attempt to tamper with the closure assembly by using a tool, instrument, etc., it is also likely to result in a disconnection of the indicator member from the housing, with again, any such removal or disconnection of the indicator member, in whole or in part, from the housing providing a clear visual indication of attempted tampering or use.
Additionally, the closure assembly of the present invention may comprise a frangible connection between the outer circumferential portions of the indicator ring and the inner peripheral surfaces of the cover. More specifically, the indicator member or indicator ring may include an outer circumferential surface that is removably connected to an inner periphery of the cover, and wherein some of the exposed portions of the indicator member and the cover may be substantially co-planar. In one or more embodiments, this frangible connection may comprise a plurality of frangible tabs, collectively disposed along at least a majority of the outer circumference of the indicator member and on an inner periphery of the annular cover, or alternatively, along the entirety thereof. In other embodiments, the frangible connection may comprise an elongated, curvilinear frangible seam as described subsequently herein.
These and other objects, features and advantages of the present invention will become clearer when the drawings as well as the detailed description are taken into consideration.
For a fuller understanding of the nature of the present invention, reference should be had to the following detailed description taken in connection with the accompanying drawings in which:
As represented in the accompanying Figures, the present invention is directed to a closure assembly, generally indicated as 10, and structured to have tamper evident capabilities, which prevent or restrict undetected access to the interior and/or contents of a medical device. The closure assembly 10 is structured to be connected to a medical device 100 such as, but not limited to, a pre-loaded syringe or other pre-loaded administering device.
With primary reference to
Still referring to the illustrated embodiment of
As is also shown in
More specifically, and with reference now to at least
The closure assembly 10 of the present invention is also structured to have tamper evident capabilities, as briefly described above. Accordingly, the closure assembly 10 includes an indicator member, generally indicated as 40 in
Therefore, the indicator member 40, 40′ can be described as being in a removal restricting relation to the tip cap 20, both before and after its intended attachment to the syringe 100 or another medical device. In practical terms, before the syringe 100 is attached to the tip cap 20 of the closure assembly 10, the tip cap 20 may be both movably and removably disposed within the hollow interior 18 of the housing 12. The disposition, dimension and overall structuring of the indicator member 40, 40′ prevents the tip cap 20 from being inadvertently or purposely removed from the interior 18 of the housing 12, without removal or disconnection of the indicator member 40, 40′ from the cover 30. As can be appreciated, any such disconnection of the indicator member or ring 40, 40′ will provide a clear indication of tampering or attempted use of the closure assembly 10.
As described above, the indicator member or indicator ring 40, 40′ is removably connected to the cover 30 in the illustrated embodiment. In more specific terms, and as shown in
Additionally, and as shown in
With primary reference now to
Additionally, and as shown in
The purpose and presence of the inner peripheral portion 49 and its relation to the exterior surface of the collar 28, is to prevent or significantly restrict the entry of a tool, instrument, or other tampering device through the access opening 42 of the indicator member or ring 40, and into the hollow interior 18 of the housing 12, when the syringe 100 is attached to the tip cap 20. In turn, this will prevent or restrict access to the drug or other contents of syringe 100 or other medical device to which the closure assembly 10 is attached.
As further represented throughout the accompanying Figures, the closure assembly 10 is initially assembled with the tip cap 20 disposed within the hollow interior 18 of the housing 12, prior to the fixed, snap-fit connection of the cover 30 to the open end 16. In other words, once the tip cap 20 has been inserted into the housing 12, the cover 30 will be fixedly secured to the open end 16 by the preferred snap-fit interlocking connection described previously herein between the depending skirt 32 of the cover 30 and the circumferential exterior lip 34, contiguous to the open and 16. Once assembled, the closure assembly 10 is ready to be attached to a medical device, such as syringe 100 that has been pre-loaded with a drug or other prescribed medical solution. In the illustrated embodiments, the discharge port 24 of the syringe 100 is inserted through the access opening 42 of the indicator member 40 or 40′. Once so inserted, the nozzle 25 or other corresponding portion of the discharge port 24 will pass into the interior chamber or receiving channel 29 of the flow restricting portion 22 of the tip cap 20, thereby establishing a flow restricting connection therebetween.
Additionally, and as perhaps best illustrated in
Once the closure assembly 10 of the present invention is installed or attached onto a syringe 100 or other medical device, to access or use the contents of the syringe 100, whether authorized or unauthorized, one must exert a pulling force on either the syringe 100 or the housing 12 or both, in the manner schematically represented by the directional arrows 200 shown in
In more specific terms, and with regard to the embodiment of
With regard to the embodiment of
Since many modifications, variations and changes in detail can be made to the described preferred embodiment of the invention, it is intended that all matters in the foregoing description and shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense. Thus, the scope of the invention should be determined by the appended claims and their legal equivalents.
This is a Non-Provisional patent application that claims priority pursuant to 35 U.S.C. Section 119(e) to a currently pending and prior filed Provisional patent application, namely, that having Ser. No. 62/478,867 filed on Mar. 30, 2017.
Number | Name | Date | Kind |
---|---|---|---|
732662 | Smith | Jun 1903 | A |
1678991 | Marschalek | Jul 1928 | A |
1970631 | Sherman | Aug 1934 | A |
2477598 | Hain | Aug 1949 | A |
2739590 | Yochem | Mar 1956 | A |
2823674 | Yochem | Feb 1958 | A |
2834346 | Adams | May 1958 | A |
2875761 | Helmer et al. | Mar 1959 | A |
2888015 | Hunt | May 1959 | A |
2952255 | Hein, Jr. | Sep 1960 | A |
3122280 | Goda | Feb 1964 | A |
3245567 | Knight | Apr 1966 | A |
3323798 | Miller | Jun 1967 | A |
3364890 | Andersen | Jan 1968 | A |
3368673 | Johnson | Feb 1968 | A |
3598120 | Mass | Aug 1971 | A |
3610241 | LeMarie | Oct 1971 | A |
3700215 | Hardman et al. | Oct 1972 | A |
3706307 | Hasson | Dec 1972 | A |
3712749 | Roberts | Jan 1973 | A |
3747751 | Miller et al. | Jul 1973 | A |
3872867 | Killinger | Mar 1975 | A |
3904033 | Haerr | Sep 1975 | A |
3905375 | Toyama | Sep 1975 | A |
3937211 | Merten | Feb 1976 | A |
4005739 | Winchell | Feb 1977 | A |
4043334 | Brown et al. | Aug 1977 | A |
4046145 | Choksi et al. | Sep 1977 | A |
4068696 | Winchell | Jan 1978 | A |
4216585 | Hatter | Aug 1980 | A |
4216872 | Bean | Aug 1980 | A |
4244366 | Raines | Jan 1981 | A |
4252122 | Halvorsen | Feb 1981 | A |
4271972 | Thor | Jun 1981 | A |
4286591 | Raines | Sep 1981 | A |
4286640 | Knox et al. | Sep 1981 | A |
4313539 | Raines | Feb 1982 | A |
4369781 | Gilson et al. | Jan 1983 | A |
4420085 | Wilson et al. | Dec 1983 | A |
4430077 | Mittleman et al. | Feb 1984 | A |
4457445 | Hanks et al. | Jul 1984 | A |
D277783 | Beck | Feb 1985 | S |
4521237 | Logothetis | Jun 1985 | A |
4530697 | Kuhlemann et al. | Jul 1985 | A |
4571242 | Klein et al. | Feb 1986 | A |
4589171 | McGill | May 1986 | A |
4664259 | Landis | May 1987 | A |
4667837 | Vitello | May 1987 | A |
4676530 | Nordgren et al. | Jun 1987 | A |
4693707 | Dye | Sep 1987 | A |
4726483 | Drozd | Feb 1988 | A |
4743229 | Chu | May 1988 | A |
4743231 | Kay et al. | May 1988 | A |
4760847 | Vaillancourt | Aug 1988 | A |
4813564 | Cooper et al. | Mar 1989 | A |
4832695 | Rosenberg et al. | May 1989 | A |
4834706 | Beck et al. | May 1989 | A |
4842592 | Caggiani et al. | Jun 1989 | A |
4844906 | Hermelin et al. | Jul 1989 | A |
4906231 | Young | Mar 1990 | A |
4919285 | Roof et al. | Apr 1990 | A |
4936445 | Grabenkort | Jun 1990 | A |
5009323 | Montgomery et al. | Apr 1991 | A |
5049129 | Zdeb et al. | Sep 1991 | A |
5057093 | Clegg et al. | Oct 1991 | A |
D323392 | Byrne | Jan 1992 | S |
5135496 | Vetter et al. | Aug 1992 | A |
5165560 | Ennis, III et al. | Nov 1992 | A |
5230429 | Etheredge, III | Jul 1993 | A |
5267983 | Oilschlager et al. | Dec 1993 | A |
5292308 | Ryan | Mar 1994 | A |
5293993 | Yates, Jr. et al. | Mar 1994 | A |
5295599 | Smith | Mar 1994 | A |
5312367 | Nathan | May 1994 | A |
5312368 | Haynes | May 1994 | A |
5328466 | Denmark | Jul 1994 | A |
5328474 | Raines | Jul 1994 | A |
5356380 | Hoekwater et al. | Oct 1994 | A |
5380295 | Vacca | Jan 1995 | A |
5405339 | Kohnen et al. | Apr 1995 | A |
5456668 | Ogle, II | Oct 1995 | A |
5458580 | Hajishoreh | Oct 1995 | A |
5468224 | Souryal | Nov 1995 | A |
5531695 | Swisher | Jul 1996 | A |
5540666 | Barta et al. | Jul 1996 | A |
5549571 | Sak | Aug 1996 | A |
5558648 | Shields | Sep 1996 | A |
5584817 | van den Haak | Dec 1996 | A |
5588239 | Anderson | Dec 1996 | A |
5624402 | Imbert | Apr 1997 | A |
5674209 | Yarger | Oct 1997 | A |
5695470 | Roussigne et al. | Dec 1997 | A |
5700247 | Grimard et al. | Dec 1997 | A |
5702374 | Johnson | Dec 1997 | A |
5713485 | Liff et al. | Feb 1998 | A |
5776124 | Wald | Jul 1998 | A |
5785691 | Vetter et al. | Jul 1998 | A |
5797885 | Rubin | Aug 1998 | A |
5807343 | Tucker et al. | Sep 1998 | A |
D402766 | Smith et al. | Dec 1998 | S |
5883806 | Meador et al. | Mar 1999 | A |
5884457 | Ortiz et al. | Mar 1999 | A |
5902269 | Jentzen | May 1999 | A |
5951522 | Rosato et al. | Sep 1999 | A |
5951525 | Thorne et al. | Sep 1999 | A |
5954657 | Rados | Sep 1999 | A |
5957166 | Safabash | Sep 1999 | A |
5963136 | O'Brien | Oct 1999 | A |
5989227 | Vetter et al. | Nov 1999 | A |
5993437 | Raoz | Nov 1999 | A |
6000548 | Tsals | Dec 1999 | A |
D419671 | Jansen | Jan 2000 | S |
6021824 | Larsen et al. | Feb 2000 | A |
6027482 | Imbert | Feb 2000 | A |
6068614 | Kimber et al. | May 2000 | A |
D430293 | Jansen | Aug 2000 | S |
D431864 | Jansen | Oct 2000 | S |
6126640 | Tucker et al. | Oct 2000 | A |
6190364 | Imbert | Feb 2001 | B1 |
6193688 | Balestracci et al. | Feb 2001 | B1 |
6196593 | Petrick et al. | Mar 2001 | B1 |
6196998 | Jansen et al. | Mar 2001 | B1 |
6235376 | Miyazaki et al. | May 2001 | B1 |
6280418 | Reinhard et al. | Aug 2001 | B1 |
6287671 | Bright et al. | Sep 2001 | B1 |
6322543 | Singh et al. | Nov 2001 | B1 |
6338200 | Baxa et al. | Jan 2002 | B1 |
6375640 | Teraoka | Apr 2002 | B1 |
6394983 | Mayoral et al. | May 2002 | B1 |
6485460 | Eakins et al. | Nov 2002 | B2 |
6500155 | Sasso | Dec 2002 | B2 |
6520935 | Jansen et al. | Feb 2003 | B1 |
6540697 | Chen | Apr 2003 | B2 |
6565529 | Kimber et al. | May 2003 | B1 |
6581792 | Limanjaya | Jun 2003 | B1 |
6585691 | Vitello | Jul 2003 | B1 |
6592251 | Edwards et al. | Jul 2003 | B2 |
6666852 | Niedospial, Jr. | Dec 2003 | B2 |
6682798 | Kiraly | Jan 2004 | B1 |
6726652 | Eakins et al. | Apr 2004 | B2 |
6726672 | Hanley et al. | Apr 2004 | B1 |
6755220 | Castellano et al. | Jun 2004 | B2 |
6764469 | Broselow | Jul 2004 | B2 |
6796586 | Werth | Sep 2004 | B2 |
6821268 | Balestracci | Nov 2004 | B2 |
D501549 | McAllister et al. | Feb 2005 | S |
6921383 | Vitello | Jul 2005 | B2 |
6935560 | Andreasson et al. | Aug 2005 | B2 |
6942643 | Eakins et al. | Sep 2005 | B2 |
7055273 | Roshkoff | Jun 2006 | B2 |
7125397 | Woehr et al. | Oct 2006 | B2 |
7141286 | Kessler et al. | Nov 2006 | B1 |
7175081 | Andreasson et al. | Feb 2007 | B2 |
7182256 | Andreasson et al. | Feb 2007 | B2 |
7232066 | Andreasson et al. | Jun 2007 | B2 |
7240926 | Dalle et al. | Jul 2007 | B2 |
7299981 | Hickle et al. | Nov 2007 | B2 |
7374555 | Heinz et al. | May 2008 | B2 |
7404500 | Marteau et al. | Jul 2008 | B2 |
7410803 | Nollert et al. | Aug 2008 | B2 |
7425208 | Vitello | Sep 2008 | B1 |
7437972 | Yeager | Oct 2008 | B2 |
7482166 | Nollert et al. | Jan 2009 | B2 |
7588563 | Guala | Sep 2009 | B2 |
7594681 | DeCarlo | Sep 2009 | B2 |
7608057 | Woehr et al. | Oct 2009 | B2 |
7611487 | Woehr et al. | Nov 2009 | B2 |
7632244 | Buehler et al. | Dec 2009 | B2 |
D608900 | Giraud et al. | Jan 2010 | S |
7641636 | Moesli et al. | Jan 2010 | B2 |
D612939 | Boone, III et al. | Mar 2010 | S |
7681606 | Khan et al. | Mar 2010 | B2 |
7698180 | Fago et al. | Apr 2010 | B2 |
7735664 | Peters et al. | Jun 2010 | B1 |
7748892 | McCoy | Jul 2010 | B2 |
7762988 | Vitello | Jul 2010 | B1 |
7766919 | Delmotte | Aug 2010 | B2 |
7802313 | Czajka | Sep 2010 | B2 |
7918830 | Langan et al. | Apr 2011 | B2 |
7922213 | Werth | Apr 2011 | B2 |
8034041 | Domkowski | Oct 2011 | B2 |
8079518 | Turner et al. | Dec 2011 | B2 |
8091727 | Domkowski | Jan 2012 | B2 |
8118788 | Frezza | Feb 2012 | B2 |
8137324 | Bobst | Mar 2012 | B2 |
8140349 | Hanson et al. | Mar 2012 | B2 |
8252247 | Ferlic | Aug 2012 | B2 |
8257286 | Meyer et al. | Sep 2012 | B2 |
8328082 | Bochenko et al. | Dec 2012 | B1 |
8348895 | Vitello | Jan 2013 | B1 |
8353869 | Ranalletta et al. | Jan 2013 | B2 |
8443999 | Reinders | May 2013 | B1 |
D684057 | Kwon | Jun 2013 | S |
8512277 | Del Vecchio | Aug 2013 | B2 |
8556074 | Turner et al. | Oct 2013 | B2 |
8579116 | Pether et al. | Nov 2013 | B2 |
8591462 | Vitello | Nov 2013 | B1 |
8597255 | Emmott et al. | Dec 2013 | B2 |
8597271 | Langan et al. | Dec 2013 | B2 |
8616413 | Koyama | Dec 2013 | B2 |
D701304 | Lair et al. | Mar 2014 | S |
8672902 | Ruan et al. | Mar 2014 | B2 |
8702674 | Bochenko | Apr 2014 | B2 |
8777910 | Bauss et al. | Jul 2014 | B2 |
8777930 | Swisher et al. | Jul 2014 | B2 |
8852561 | Wagner et al. | Oct 2014 | B2 |
8864021 | Vitello | Oct 2014 | B1 |
8864707 | Vitello | Oct 2014 | B1 |
8864708 | Vitello | Oct 2014 | B1 |
8911424 | Weadock et al. | Dec 2014 | B2 |
8945082 | Geiger et al. | Feb 2015 | B2 |
9082157 | Gibson | Jul 2015 | B2 |
9101534 | Bochenko | Aug 2015 | B2 |
D738495 | Strong et al. | Sep 2015 | S |
D743019 | Schultz | Nov 2015 | S |
9199042 | Farrar et al. | Dec 2015 | B2 |
9199749 | Vitello | Dec 2015 | B1 |
9220486 | Schweiss et al. | Dec 2015 | B2 |
9220577 | Jessop et al. | Dec 2015 | B2 |
9227019 | Swift et al. | Jan 2016 | B2 |
D750228 | Strong et al. | Feb 2016 | S |
9272099 | Limaye et al. | Mar 2016 | B2 |
9311592 | Vitello et al. | Apr 2016 | B1 |
D756777 | Berge et al. | May 2016 | S |
9336669 | Bowden et al. | May 2016 | B2 |
D759486 | Ingram et al. | Jun 2016 | S |
D760384 | Niunoya et al. | Jun 2016 | S |
D760902 | Persson | Jul 2016 | S |
9402967 | Vitello | Aug 2016 | B1 |
9427715 | Palazzolo et al. | Aug 2016 | B2 |
9433768 | Tekeste et al. | Sep 2016 | B2 |
9463310 | Vitello | Oct 2016 | B1 |
D773043 | Insgram et al. | Nov 2016 | S |
D777903 | Schultz | Mar 2017 | S |
9662456 | Woehr | May 2017 | B2 |
D789529 | Davis et al. | Jun 2017 | S |
9687249 | Hanlon et al. | Jun 2017 | B2 |
9744304 | Swift et al. | Aug 2017 | B2 |
D797928 | Davis et al. | Sep 2017 | S |
D797929 | Davis et al. | Sep 2017 | S |
9764098 | Hund et al. | Sep 2017 | B2 |
9821152 | Vitello et al. | Nov 2017 | B1 |
D806241 | Swinney et al. | Dec 2017 | S |
D807503 | Davis et al. | Jan 2018 | S |
9855191 | Vitello et al. | Jan 2018 | B1 |
D815945 | Fischer | Apr 2018 | S |
9987438 | Stillson | Jun 2018 | B2 |
D825746 | Davis et al. | Aug 2018 | S |
10039913 | Yeh et al. | Aug 2018 | B2 |
D831201 | Holtz et al. | Oct 2018 | S |
D820187 | Ryan | Nov 2018 | S |
10124122 | Zenker | Nov 2018 | B2 |
10166343 | Hunt et al. | Jan 2019 | B1 |
10166347 | Vitello | Jan 2019 | B1 |
10183129 | Vitello | Jan 2019 | B1 |
10207099 | Vitello | Feb 2019 | B1 |
D842464 | Davis et al. | Mar 2019 | S |
D847373 | Hurwit et al. | Apr 2019 | S |
10300263 | Hunt | May 2019 | B1 |
10307548 | Hunt et al. | Jun 2019 | B1 |
10315024 | Vitello et al. | Jun 2019 | B1 |
10376655 | Pupke et al. | Aug 2019 | B2 |
D859125 | Weagle et al. | Sep 2019 | S |
10758684 | Vitello et al. | Sep 2020 | B1 |
10898659 | Vitello et al. | Jan 2021 | B1 |
10912898 | Vitello et al. | Feb 2021 | B1 |
10933202 | Banik | Mar 2021 | B1 |
10953162 | Hunt et al. | Mar 2021 | B1 |
20010034506 | Hirschman et al. | Oct 2001 | A1 |
20010056258 | Evans | Dec 2001 | A1 |
20020007147 | Capes et al. | Jan 2002 | A1 |
20020023409 | Py | Feb 2002 | A1 |
20020097396 | Schafer | Jul 2002 | A1 |
20020099334 | Hanson et al. | Jul 2002 | A1 |
20020101656 | Blumenthal et al. | Aug 2002 | A1 |
20020133119 | Eakins et al. | Sep 2002 | A1 |
20030055685 | Cobb et al. | Mar 2003 | A1 |
20030146617 | Franko, Sr. | Aug 2003 | A1 |
20030183547 | Heyman | Oct 2003 | A1 |
20040008123 | Carrender et al. | Jan 2004 | A1 |
20040064095 | Vitello | Apr 2004 | A1 |
20040116858 | Heinz et al. | Jun 2004 | A1 |
20040186437 | Frenette et al. | Sep 2004 | A1 |
20040225258 | Balestracci | Nov 2004 | A1 |
20050146081 | MacLean et al. | Jul 2005 | A1 |
20050148941 | Farrar et al. | Jul 2005 | A1 |
20050209555 | Middleton et al. | Sep 2005 | A1 |
20060084925 | Ramsahoye | Apr 2006 | A1 |
20060089601 | Dionigi | Apr 2006 | A1 |
20060173415 | Cummins | Aug 2006 | A1 |
20060189933 | Alheidt et al. | Aug 2006 | A1 |
20070060898 | Shaughnessy et al. | Mar 2007 | A1 |
20070106234 | Klein | May 2007 | A1 |
20070142786 | Lampropoulos et al. | Jun 2007 | A1 |
20070191690 | Hasse et al. | Aug 2007 | A1 |
20070219503 | Loop et al. | Sep 2007 | A1 |
20070257111 | Ortenzi | Nov 2007 | A1 |
20080068178 | Meyer | Mar 2008 | A1 |
20080097310 | Buehler et al. | Apr 2008 | A1 |
20080106388 | Knight | May 2008 | A1 |
20080140020 | Shirley | Jun 2008 | A1 |
20080243088 | Evans | Oct 2008 | A1 |
20080306443 | Neer | Dec 2008 | A1 |
20090084804 | Caspary | Apr 2009 | A1 |
20090099552 | Levy et al. | Apr 2009 | A1 |
20090149815 | Kiel et al. | Jun 2009 | A1 |
20090326481 | Swisher et al. | Dec 2009 | A1 |
20100084403 | Popish et al. | Apr 2010 | A1 |
20100126894 | Koukol et al. | May 2010 | A1 |
20100179822 | Reppas | Jul 2010 | A1 |
20100228226 | Nielsen | Sep 2010 | A1 |
20100252564 | Martinez et al. | Oct 2010 | A1 |
20100283238 | Deighan et al. | Nov 2010 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110046550 | Schiller et al. | Feb 2011 | A1 |
20110046603 | Felsovalyi et al. | Feb 2011 | A1 |
20120064515 | Knapp et al. | Mar 2012 | A2 |
20120096957 | Ochman | Apr 2012 | A1 |
20120110950 | Schraudolph | May 2012 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130056130 | Alpert et al. | Mar 2013 | A1 |
20130088354 | Thomas | Apr 2013 | A1 |
20130237949 | Miller | Sep 2013 | A1 |
20130269592 | Heacock et al. | Oct 2013 | A1 |
20140000781 | Franko, Jr. | Jan 2014 | A1 |
20140034536 | Reinhardt et al. | Feb 2014 | A1 |
20140069202 | Fisk | Mar 2014 | A1 |
20140069829 | Evans | Mar 2014 | A1 |
20140135738 | Panian | May 2014 | A1 |
20140155868 | Nelson et al. | Jun 2014 | A1 |
20140163465 | Bartlett, II et al. | Jun 2014 | A1 |
20140257843 | Adler et al. | Sep 2014 | A1 |
20140326727 | Jouin et al. | Nov 2014 | A1 |
20140353196 | Key | Dec 2014 | A1 |
20150182686 | Okihara | Jul 2015 | A1 |
20150191633 | De Boer et al. | Jul 2015 | A1 |
20150305982 | Bochenko | Oct 2015 | A1 |
20150310771 | Atkinson et al. | Oct 2015 | A1 |
20160067422 | Davis et al. | Mar 2016 | A1 |
20160090456 | Ishimaru et al. | Mar 2016 | A1 |
20160144119 | Limaye et al. | May 2016 | A1 |
20160158110 | Swisher et al. | Jun 2016 | A1 |
20160158449 | Limaye et al. | Jun 2016 | A1 |
20160176550 | Vitello et al. | Jun 2016 | A1 |
20160328586 | Bowden et al. | Nov 2016 | A1 |
20160361235 | Swisher | Dec 2016 | A1 |
20160367439 | Davis et al. | Dec 2016 | A1 |
20170007771 | Duinat et al. | Jan 2017 | A1 |
20170014310 | Hyun et al. | Jan 2017 | A1 |
20170124289 | Hasan et al. | May 2017 | A1 |
20170173321 | Davis et al. | Jun 2017 | A1 |
20170203086 | Davis | Jul 2017 | A1 |
20170319438 | Davis et al. | Nov 2017 | A1 |
20170354792 | Ward | Dec 2017 | A1 |
20180001540 | Byun | Jan 2018 | A1 |
20180078684 | Peng et al. | Mar 2018 | A1 |
20180089593 | Patel et al. | Mar 2018 | A1 |
Number | Date | Country |
---|---|---|
0148116 | Jul 1985 | EP |
486367 | Jun 1938 | GB |
WO 2008000279 | Jan 2008 | WO |
WO 2017086607 | May 2015 | WO |
Number | Date | Country | |
---|---|---|---|
62478867 | Mar 2017 | US |